Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pegfilgrastim Biosimilars Market Grown from 2024 to 2025?

The market size for pegfilgrastim biosimilars has seen an accelerated growth in the past few years. It is projected to increase from $1.56 billion in 2024 to $1.8 billion in 2025, representing a compound annual growth rate (CAGR) of 15.3%. The remarkable expansion in the historical period is due to several factors including higher cancer incidence rates, government interventions, augmenting healthcare spending, boost in biopharmaceutical R&D expenditures, lower prices of biosimilars, and widespread use of these biosimilar medications.

What Growth Rate Is Anticipated for the Pegfilgrastim Biosimilars Market in the Coming Years?

In the coming years, the pegfilgrastim biosimilars market is projected to experience fast-paced expansion, with its value estimated to reach $3.44 billion in 2029, growing at a compound annual growth rate (CAGR) of 17.5%. This predicted growth during the forecast timeframe can be ascribed to the escalating prevalence of cancer, older demographic, a rise in the number of approvals, as well as targets and incentives. Major trends for the forecast period includes exploiting more liberal regulations for the creation of advanced biosimilars, substantial investment in R&D for the production of innovative and efficient biologics, strong emphasis on fostering strategic collaborations with major players to broaden their R&D activities in new medication developments, and an increased focus on mergers and acquisitions to broaden both their customer base and regional markets. There is also an increasing focus on the production of biosimilars for neutropenia treatment to enhance revenue and product portfolio.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Who Are the Leading Companies in the Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Reddy’s Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

What Are the Key Drivers of the Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is likely to be propelled by government efforts aimed at promoting biosimilars. Recognizing their affordability, governments globally are shifting their attention towards the growth of biosimilars. To expand treatment alternatives, the US Food and Drug Administration (FDA) implemented a Biosimilar Action Plan. The Australian government has pledged its support for the Biosimilar Awareness Initiative, bolstering their commitment by assisting the Generic and Biosimilar Medicines Association with a grant worth $5 million. This pledge supports widespread education on biosimilars and activities encouraging appropriate distribution, prescription, and utility of such medicines. Therefore, these governmental strategies aimed at biosimilar development contribute to heightening production and awareness, subsequently fostering the advancement of the pegfilgrastim biosimilars market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

What Are the Key Market Segments in the Pegfilgrastim Biosimilars Industry?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

What Are the Latest Trends in the Pegfilgrastim Biosimilars Market?

Firms in the pegfilgrastim biosimilar market are escalating their product creativity through essential collaborations. In a bid to remain relevant in the increasingly cutthroat market, firms are crafting innovative products and pooling resources and knowledge with other firms. The long-standing trend of synergy with academic and research bodies via partnerships or out-licensing contracts has surged in recent years within this market. A case in point is the partnership in May 2023, between Amneal Pharmaceuticals and Kashiv Biosciences, American companies in the generics and specialty pharmaceutical and biosciences sectors respectively. Together, they engineered and launched Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA, a preservative-free, transparent solution dispensed in a 6 mg/0.6 mL single-use prefilled syringe, is used to curb the risks of infection, notably febrile neutropenia, among patients with non-myeloid cancers undertaking certain myelosuppressive anti-cancer procedures.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What Are the Key Regional Markets in the Pegfilgrastim Biosimilars Industry?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

This Report Delivers Insight On:

1. How big is the pegfilgrastim biosimilars market, and how is it changing globally?

2. Who are the major companies in the pegfilgrastim biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the pegfilgrastim biosimilars market right now?

4. Which products or customer segments are growing the most in the pegfilgrastim biosimilars market?

5. What factors are helping or slowing down the growth of the pegfilgrastim biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model